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PERSPECTIVE
Retinal ganglion cell neuroprotection 
by growth factors and exosomes: 
lessons from mesenchymal stem cells
Retinal ganglions cells (RGCs) are responsible for propagating 
electrochemical information from the eye to the brain along 
their axons which make up the optic nerve. The loss of RGCs is 
characteristic in several conditions such as glaucoma and trau-
matic optic neuropathy and leads to visual loss and blindness. 
While no therapy exists to directly treat RGCs, the use of bone 
marrow-derived mesenchymal stem cells (BMSCs) has shown 
promise in eliciting significant RGC neuroprotection. Their ef-
ficacy is proven in both in vitro (retinal co-culture (Mead et al., 
2014) and organotypic retinal explants (Johnson et al., 2014)) 
and in vivo (ocular hypertension (Johnson et al., 2010) and optic 
nerve crush (Mesentier-Louro et al., 2014)) models from multi-
ple laboratories and are currently being investigated in clinical 
trials (reviewed in Mead et al., 2015). While other MSCs exist, 
such as those isolated from adipose tissue, umbilical cord blood 
and dental pulp, and have even been demonstrated to act differ-
ently in neuroprotective assays (Mead et al., 2014), BMSCs are 
the most widely studied and the predominant MSC undergoing 
clinical trials. Although BMSCs do not replace retinal cells and 
their mechanism of action is exclusively through the secretion 
of neuroprotective compounds, BMSCs represent an exciting 
candidate for cellular therapy of the retina. A large body of 
evidence exists for the efficacious use of BMSCs in several eye 
disease models and over ten stage 1 clinical trials are underway 
(Reviewed in Mead et al., 2015). While many of these trials have 
now reported good findings with successful transplantation into 
patients,  the safety aspect of delivering living, dividing cells into 
the eye can still be questioned given the recent case study of three 
patients going blind after receiving intravitreal adipose-derived 
MSCs (Kuriyan et al., 2017). Issues such as hemorrhage and ret-
inal detachment were observed and may reflect a possible side 
effect of intravitreal cell therapy. What is also not clear is the 
“shelf-life” of the BMSCs, particularly considering that they will 
need to be stored in liquid nitrogen, or grown and maintained at 
37°C/5% CO2. These requirements add further costs and exper-
tise needed for such a treatment while also introducing variabil-
ity, particularly since the longer the cells are grown the lower the 
titers of secreted neuroprotective compounds (Mead et al., 2014). 
Another issue is that the BMSCs secretome contains a wide va-
riety of compounds, some of which, such as vascular endothelial 
growth factor (VEGF), may be detrimental to the retina in high 
concentrations. While using BMSCs as a therapy is one avenue 
of research, understanding of their mechanism and the develop-
ment of new treatments, independent of the cells themselves is 
equally important and would circumnavigate much of the issues 
detailed above. Our research has identified two very different 
modalities by which BMSCs protect RGCs, secretion of multiple 
neuroprotective peptides, of which platelet-derived growth factor 
(PDGF)-AA was the most neuroprotective, and secretion of ex-
tracellular vesicles including exosomes.
PDGF-AA: BMSCs are known to secrete a variety of neuro-
trophic factors including nerve growth factor and brain-derived 
neurotrophic factor which through the activation of Tropomysin 
receptor kinase A (TrkA) and Tropomysin receptor kinase B 
(TrkB), elicit neuroprotection. In an effort to identify additional 
factors with neuroprotective efficacy, BMSC’s secretome was ana-
lyzed and PDGF-AA was found to be enriched in comparison to 
the secretome of fibroblasts, which unlike BMSCs lacked neuro-
protective efficacy. PDGF-AA is a homodimer that interacts with 
PDGF receptor-α (PDGFRα). Blockade of PDGFRα significantly 
reduced BMSCs neuroprotection in vitro whereas intravitreal de-
livery of recombinant PDGF-AA promoted significant neuropro-
tection of RGCs in an ocular hypertensive rat model (Johnson et 
al., 2014). A second study demonstrated in the same model that 
an intravitreal injection of PDGF-AA preserved RGCs synaptic 
density within the inner plexiform layer (Chong et al., 2016).
While we initially hypothesized that PDGF-AA would act 
directly on RGCs to elicit its neuroprotective effect, the mecha-
nism appeared more complicated given that RGCs do not express 
PDGFRα. In a recent study to elucidate the retinal targets of 
PDGF-AA, EGFP was expressed under the PDGFRα promoter 
(Takahama et al., 2017). PDGFRα expression was localized to 
astrocytes within the ganglion cell layer and Type 45 GABAergic 
wide-field amacrine cells in the inner nuclear layer. While the 
mechanism of action is yet to be confirmed, RNAseq of PDG-
FRα+ amacrine cells and astrocytes is planned to determine 
changes following PDGF-AA stimulation. We hypothesize that 
astrocytes and/or amacrine cells, in response to PDGFRα activa-
tion, secrete factors neuroprotective for injured RGCs.
Exosomes: Exosomes are small extracellular vesicles ranging 
in size between 40–100 nm. Typically in the literature they are 
often isolated through ultra-centrifugation and thus also include 
microvesicles, which are extracellular vesicles ranging in size be-
tween 100–1,000 nm. While microvesicles are released from cells 
via outward budding of the plasma membrane, exosomes are 
formed within multivesicular bodies which upon its fusion with 
the plasma membrane, are secreted into the extracellular space. 
Although we use the term “exosome”, “small extracellular vesicle” 
is also an appropriate term, since some smaller microvesicles can 
be present in the preparation. 
Exosomes contain proteins, lipids, mRNAs and microRNAs 
(miRNAs) which can be transported and delivered to other cells. 
Recipient cells can translate these mRNAs into proteins as well as 
have gene expression regulated by the miRNAs. Unlike peptides 
such as PDGF-AA, because exosomes deliver their cargo directly 
into cells, they are not dependent on the expression of specific 
receptors. We recently demonstrated that exosomes derived from 
BMSCs are able to protect RGCs from death in rat models of op-
tic nerve crush (ONC) (Mead and Tomarev, 2017) and glaucoma 
(Mead et al., 2018).
Exosomes were found to integrate indiscriminately into the 
ganglion cell layer and the neuroprotective effect was dependent 
on efficient delivery of miRNAs. Thus, unlike PDGF-AA that acts 
on the PDGFRα of astrocytes/amacrine cells, exosomes function 
through several mechanisms including the direct modulation 
of mRNAs translation through miRNA-mediated knockdown. 
Treatment of purified cultures of RGCs with exosomes, and sub-
sequent neuroprotection demonstrates that the mechanism is, 
at least partially, mediated through RGCs directly (Mead et al., 
2018). While few studies exist that have tested exosomes as a neu-
roprotective therapy, a similar observation was seen on cultured 
cortical cells, suggesting the effect is not specific to RGCs and 
thus, exosomes may benefit other injured central nervous system 
(CNS) neurons (Zhang et al., 2017). Interestingly, this group also 
attributed the effects of BMSCs exosomes to their miRNA cargo.
Our recent study highlighted over 40 miRNAs overabundant in 
BMSCs exosomes in comparison to fibroblast exosomes (Mead et 
al., 2018). The exact miRNA or combination of miRNAs respon-
sible for the exosome-mediated neuroprotection is the subject of 
our current investigations. 
Future work: BMSCs have shown great promise in several mod-
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els of retinal injury and by several groups. Since the mechanism 
of action appears to be multifactorial, a great amount can be 
learnt by studying their secretome to determine new novel neu-
roprotective pathways.
Future studies are to focus on the mRNA changes of RGCs (in 
the case of exosome treatment) and astrocytes/amacrine cells (in 
the case of PDGF-AA) treatment. By understanding the mRNA 
changes in these cell types following their respective treatments, 
the mechanism of action can be better understood. In the case 
of exosomes, cross referencing miRNAs abundantly present in 
BMSCs with mRNAs downregulated in RGCs after exosome 
treatment will further help to narrow down the signalling path-
ways responsible for the neuroprotective effect. By determining 
the miRNAs both already abundant in healthy RGCs or down-
regulated after ocular hypertension/optic nerve injury, candidate 
exosome-derived miRNAs can be further narrowed down.
By understanding the mechanism of action of each MSC-de-
rived neuroprotective compound, combinatorial therapies can 
be developed that target multiple pathways. For example, while 
it appears that PDGF-AA and exosomes work through different 
mechanisms, the downstream neuroprotective signalling path-
ways may be shared. One should also keep in mind that some 
differences may exist in the neuroprotective mechanisms activat-
ed in the human and rodent retinas. For example, a recent paper 
demonstrated that PDGF-AB but not PDGF-AA was neuropro-
tective in human retinal explant cultures. It was also demonstrat-
ed that blockade of PDGF signalling, unlike in rodent retina, did 
not reduce MSC-induced neuroprotection, suggesting greater re-
dundancy in the mechanism of action on human RGCs (Osborne 
et al., 2018). Therefore, neuroprotective compounds identified in 
rodent models should be tested in larger animal models of glau-
coma and traumatic optic neuropathy before testing in humans. 
After intravitreal transplantation, BMSCs remain in the eye 
and presumably continue to secrete neuroprotective compounds 
on the injured retina. In contrast, administration of purified 
neuroprotective compounds (exosomes or PDGF-AA) is short 
lived with the effect ranging from several days to a month. In our 
previous study utilizing a rat model of glaucoma characterized 
by 2 months of ocular hypertension, exosomes elicited neuro-
protection if injected monthly but not if injected only once at the 
beginning (Mead et al., 2018). In contrast, PDGF-AB treatment 
of human retinal wholemounts are more short lived with the pep-
tide decreasing in concentration by 80% five days after treatment 
(Osborne et al., 2018). Thus, for a cell free therapy to be effective, 
the longevity must be addressed to avoid patients needing repeat-
ed injections. 
Another important consideration is that the RGCs are not a 
homogenous population but rather, a collective of about 50 sub-
types in mice. While injury is known to differentially affect RGC 
subtypes, it is equally expected that treatment will target specific 
subtypes. The combinatorial nature of MSC’s secretome may tar-
get multiple RGC subtypes while isolating specific neuroprotec-
tive compounds may leave certain subtypes unprotected.
Conclusion: BMSCs are known to secrete many compounds 
that act therapeutically on many organs and diseases. While a 
treatment in themselves, BMSCs offer an important research tool 
to study their secretome and discover new novel signalling path-
ways that be exploited for clinical effect. 
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